Top

Published in:

Open Access 01-12-2021 | Colorectal Cancer | Review

Danish guidelines for management of non-APC-associated hereditary polyposis syndromes

Authors: Anne Marie Jelsig, John Gásdal Karstensen, Niels Jespersen, Zohreh Ketabi, Charlotte Lautrup, Karina Rønlund, Lone Sunde, Karin Wadt, Ole Thorlacius-Ussing, Niels Qvist

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2021

Abstract

Hereditary Polyposis Syndromes are a group of rare, inherited syndromes characterized by the presence of histopathologically specific or numerous intestinal polyps and an increased risk of cancer. Some polyposis syndromes have been known for decades, but the development in genetic technologies has allowed the identification of new syndromes.. The diagnosis entails surveillance from an early age, but universal guideline on how to manage and surveille these new syndromes are lacking. This paper represents a condensed version of the recent guideline (2020) from a working group appointed by the Danish Society of Medical Genetics and the Danish Society of Surgery on recommendations for the surveillance of patients with hereditary polyposis syndromes, including rare polyposis syndromes.

Available only for authorised users

Hinds R, Philp C, Hyer W, Fell JM. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr. 2004;39(2):219–20. https://doi.org/10.1097/00005176-200408000-00027.CrossRefPubMed

Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62; quiz 63. https://doi.org/10.1038/ajg.2014.435.CrossRefPubMedPubMedCentral

Brosens LA, van Hattem A, Hylind LM, Iacobuzio-Donahue C, Romans KE, Axilbund J, et al. Risk of colorectal cancer in juvenile polyposis. Gut. 2007;56(7):965–7. https://doi.org/10.1136/gut.2006.116913.CrossRefPubMedPubMedCentral

Buchanan DD, Stewart JR, Clendenning M, Rosty C, Mahmood K, Pope BJ, et al. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1. Genet Med. 2018;20(8):890–5. https://doi.org/10.1038/gim.2017.185.CrossRefPubMed

Nielsen M, Infante E, Brand R. MUTYH polyposis. 2012 Oct 4 [updated 2019 Oct 10]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK107219/.

Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, et al. Mutational signature analysis reveals NTHL1 deficiency to cause a multi-tumor phenotype. Cancer Cell. 2019;35(2):256–66 e5. https://doi.org/10.1016/j.ccell.2018.12.011.CrossRef

Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). J Med Genet. 2014;51(6):355–65. https://doi.org/10.1136/jmedgenet-2014-102284.CrossRefPubMed

Bleijenberg AG, JE IJ, van Herwaarden YJ, Carballal S, Pellise M, Jung G, et al. Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study. Gut. 2020;69(1):112–21. https://doi.org/10.1136/gutjnl-2018-318134.CrossRefPubMed

Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15. https://doi.org/10.1158/1078-0432.CCR-06-0083.CrossRefPubMed

10.

Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the international Cancer of the pancreas screening (CAPS) consortium. Gut. 2020;69(1):7–17. https://doi.org/10.1136/gutjnl-2019-319352.CrossRefPubMed

11.

Latchford A, Cohen S, Auth M, Scaillon M, Viala J, Daniels R, et al. Management of Peutz-Jeghers Syndrome in children and adolescents: a position paper from the ESPGHAN polyposis working group. J Pediatr Gastroenterol Nutr. 2019;68(3):442–52. https://doi.org/10.1097/MPG.0000000000002248.CrossRefPubMed

12.

Teekakirikul P, Milewicz DM, Miller DT, Lacro RV, Regalado ES, Rosales AM, et al. Thoracic aortic disease in two patients with juvenile polyposis syndrome and SMAD4 mutations. Am J Med Genet A. 2013;161A(1):185–91. https://doi.org/10.1002/ajmg.a.35659.CrossRefPubMed

13.

Jelsig AM, Brusgaard K, Hansen TP, Qvist N, Larsen M, Bojesen A, et al. Germline variants in Hamartomatous polyposis syndrome-associated genes from patients with one or few hamartomatous polyps. Scand J Gastroenterol. 2016;51(9):1118–25. https://doi.org/10.1080/00365521.2016.1174880.CrossRefPubMed

14.

Blatter R, Tschupp B, Aretz S, Bernstein I, Colas C, Evans DG, et al. Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers. Genet Med. 2020;22(9):1524–32. https://doi.org/10.1038/s41436-020-0826-1.CrossRefPubMedPubMedCentral

15.

Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45(2):136–44. https://doi.org/10.1038/ng.2503.CrossRefPubMed

16.

Valle L, Hernandez-Illan E, Bellido F, Aiza G, Castillejo A, Castillejo MI, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet. 2014;23(13):3506–12. https://doi.org/10.1093/hmg/ddu058.CrossRef

17.

Bellido F, Pineda M, Aiza G, Valdes-Mas R, Navarro M, Puente DA, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325–32. https://doi.org/10.1038/gim.2015.75.CrossRefPubMed

18.

Rosner G, Gluck N, Carmi S, Bercovich D, Fliss-Issakov N, Ben-Yehoyada M, et al. POLD1 and POLE gene mutations in Jewish cohorts of early-onset colorectal Cancer and of multiple colorectal adenomas. Dis Colon Rectum. 2018;61(9):1073–9. https://doi.org/10.1097/DCR.0000000000001150.CrossRef

19.

Lindsay H, Scollon S, Reuther J, Voicu H, Rednam SP, Lin FY, et al. Germline POLE mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. Cold Spring Harbor Mol Case Stud. 2019;5(5):a004499. https://doi.org/10.1101/mcs.a004499.CrossRef

20.

Wimmer K, Beilken A, Nustede R, Ripperger T, Lamottke B, Ure B, et al. A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency. Familial Cancer. 2017;16(1):67–71. https://doi.org/10.1007/s10689-016-9925-1.CrossRefPubMed

21.

Rohlin A, Rambech E, Kvist A, Torngren T, Eiengard F, Lundstam U, et al. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing. Familial Cancer. 2017;16(2):195–203. https://doi.org/10.1007/s10689-016-9934-0.CrossRefPubMed

22.

Rivera B, Perea J, Sanchez E, Villapun M, Sanchez-Tome E, Mercadillo F, et al. A novel AXIN2 germline variant associated with attenuated FAP without signs of oligondontia or ectodermal dysplasia. Eur J Hum Genet. 2014;22(3):423–6. https://doi.org/10.1038/ejhg.2013.146.CrossRefPubMed

23.

El Hachem N, Abadie C, Longy M, Colas C, Fert-Ferrer S, Leroux D, et al. Endoscopic phenotype of Monoallelic carriers of MUTYH gene mutations in the family of polyposis patients: a prospective study. Dis Colon Rectum. 2019;62(4):470–5. https://doi.org/10.1097/DCR.0000000000001323.CrossRefPubMed

24.

Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology. 2014;146:1208–11 e1–5.CrossRef

25.

van Leerdam ME, Roos VH, van Hooft JE, Dekker E, Jover R, Kaminski MF, et al. Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2019;51(9):877–95. https://doi.org/10.1055/a-0965-0605.CrossRefPubMed

26.

Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet. 2015;47(6):668–71. https://doi.org/10.1038/ng.3287.CrossRef

27.

Rivera B, Castellsague E, Bah I, van Kempen LC, Foulkes WD. Biallelic NTHL1 mutations in a woman with multiple primary tumors. N Engl J Med. 2015;373(20):1985–6. https://doi.org/10.1056/NEJMc1506878.CrossRefPubMed

28.

Belhadj S, Quintana I, Mur P, Munoz-Torres PM, Alonso MH, Navarro M, et al. NTHL1 biallelic mutations seldom cause colorectal cancer, serrated polyposis or a multi-tumor phenotype, in absence of colorectal adenomas. Sci Rep. 2019;9(1):9020. https://doi.org/10.1038/s41598-019-45281-1.CrossRefPubMedPubMedCentral

29.

Fostira F, Kontopodis E, Apostolou P, Fragkaki M, Androulakis N, Yannoukakos D, et al. Extending the clinical phenotype associated with biallelic NTHL1 germline mutations. Clin Genet. 2018;94(6):588–9. https://doi.org/10.1111/cge.13444.CrossRefPubMed

30.

Groves A, Gleeson M, Spigelman AD. NTHL1-associate polyposis: first Australian case report. Familial Cancer. 2019;18(2):179–82. https://doi.org/10.1007/s10689-018-0107-1.CrossRefPubMed

31.

Broderick P, Dobbins SE, Chubb D, Kinnersley B, Dunlop MG, Tomlinson I, et al. Validation of recently proposed colorectal Cancer susceptibility gene variants in an analysis of families and patients-a systematic review. Gastroenterology. 2017;152(1):75–7 e4. https://doi.org/10.1053/j.gastro.2016.09.041.CrossRefPubMed

32.

Altaraihi M, Gerdes AM, Wadt K. A new family with a homozygous nonsense variant in NTHL1 further delineated the clinical phenotype of NTHL1-associated polyposis. Hum Genome Variation. 2019;6(1):46. https://doi.org/10.1038/s41439-019-0077-3.CrossRef

33.

Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer. 2014;50:987–96.CrossRef

34.

Vasen HF, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European consortium "care for CMMR-D" (C4CMMR-D). J Med Genet. 2014;51(5):283–93. https://doi.org/10.1136/jmedgenet-2013-102238.CrossRefPubMed

35.

Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, et al. Exome sequencing identifies Biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet. 2016;99(2):337–51. https://doi.org/10.1016/j.ajhg.2016.06.015.CrossRefPubMedPubMedCentral

36.

Olkinuora A, Nieminen TT, Martensson E, Rohlin A, Ristimaki A, Koskenvuo L, et al. Biallelic germline nonsense variant of MLH3 underlies polyposis predisposition. Genet Med. 2019;21(8):1868–73. https://doi.org/10.1038/s41436-018-0405-x.CrossRefPubMed

37.

Whitelaw SC, Murday VA, Tomlinson IP, Thomas HJ, Cottrell S, Ginsberg A, et al. Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology. 1997;112(2):327–34. https://doi.org/10.1053/gast.1997.v112.pm9024286.CrossRefPubMed

38.

Jaeger E, Leedham S, Lewis A, Segditsas S, Becker M, Cuadrado PR, et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet. 2012;44(6):699–703. https://doi.org/10.1038/ng.2263.CrossRefPubMedPubMedCentral

39.

McKenna DB, Van Den Akker J, Zhou AY, Ryan L, Leon A, O'Connor R, et al. Identification of a novel GREM1 duplication in a patient with multiple colon polyps. Familial Cancer. 2019;18(1):63–6. https://doi.org/10.1007/s10689-018-0090-6.CrossRefPubMedPubMedCentral

40.

Lieberman S, Walsh T, Schechter M, Adar T, Goldin E, Beeri R, et al. Features of patients with hereditary mixed polyposis syndrome caused by duplication of GREM1 and implications for screening and surveillance. Gastroenterology. 2017;152(8):1876–80 e1. https://doi.org/10.1053/j.gastro.2017.02.014.CrossRefPubMed

41.

Tomlinson I, Rahman N, Frayling I, Mangion J, Barfoot R, Hamoudi R, et al. Inherited susceptibility to colorectal adenomas and carcinomas: evidence for a new predisposition gene on 15q14-q22. Gastroenterology. 1999;116(4):789–95. https://doi.org/10.1016/S0016-5085(99)70061-2.CrossRefPubMed

42.

Bleijenberg AG, Je IJ, van Herwaarden YJ, Carballal S, Pellise M, Jung G, et al. Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study. Gut. 2020;69(1):112–21. https://doi.org/10.1136/gutjnl-2018-318134.CrossRefPubMed

43.

Jeg IJ, Bevan R, Senore C, Kaminski MF, Kuipers EJ, Mroz A, et al. Detection rate of serrated polyps and serrated polyposis syndrome in colorectal cancer screening cohorts: a European overview. Gut. 2017;66(7):1225–32. https://doi.org/10.1136/gutjnl-2015-310784.CrossRef

44.

Yan HHN, Lai JCW, Ho SL, Leung WK, Law WL, Lee JFY, et al. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut. 2017;66(9):1645–56. https://doi.org/10.1136/gutjnl-2016-311849.CrossRefPubMed

45.

Buchanan DD, Clendenning M, Zhuoer L, Stewart JR, Joseland S, Woodall S, et al. Lack of evidence for germline RNF43 mutations in patients with serrated polyposis syndrome from a large multinational study. Gut. 2017;66(6):1170–2. https://doi.org/10.1136/gutjnl-2016-312773.CrossRefPubMed

46.

Win AK, Walters RJ, Buchanan DD, Jenkins MA, Sweet K, Frankel WL, et al. Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol. 2012;107(5):770–8. https://doi.org/10.1038/ajg.2012.52.CrossRefPubMedPubMedCentral

47.

Tieu AH, Edelstein D, Axilbund J, Romans KE, Brosens LA, Wiley E, et al. Clinical characteristics of multiple colorectal adenoma patients without germline APC or MYH mutations. J Clin Gastroenterol. 2016;50(7):584–8. https://doi.org/10.1097/MCG.0000000000000416.CrossRefPubMedPubMedCentral

48.

Kallenberg FGJ, Latchford A, Lips NC, Aalfs CM, Bastiaansen BAJ, Clark SK, et al. Duodenal adenomas in patients with multiple colorectal adenomas without germline APC or MUTYH mutations. Dis Colon Rectum. 2018;61(1):58–66. https://doi.org/10.1097/DCR.0000000000000868.CrossRefPubMed

49.

Giarola M, Stagi L, Presciuttini S, Mondini P, Radice MT, Sala P, et al. Screening for mutations of the APC gene in 66 Italian familial adenomatous polyposis patients: evidence for phenotypic differences in cases with and without identified mutation. Hum Mutat. 1999;13(2):116–23. https://doi.org/10.1002/(SICI)1098-1004(1999)13:2<116::AID-HUMU3>3.0.CO;2-2.

Title: Danish guidelines for management of non-APC-associated hereditary polyposis syndromes
Authors: Anne Marie Jelsig
John Gásdal Karstensen
Niels Jespersen
Zohreh Ketabi
Charlotte Lautrup
Karina Rønlund
Lone Sunde
Karin Wadt
Ole Thorlacius-Ussing
Niels Qvist
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: Hereditary Cancer in Clinical Practice / Issue 1/2021
Electronic ISSN: 1897-4287
DOI: https://doi.org/10.1186/s13053-021-00197-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

CD36 polymorphisms and the age of disease onset in patients with pathogenic variants within the mutation cluster region of APC

Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma

Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review

A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review

Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients

Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline

Keynote webinar | Spotlight on antibody–drug conjugates in cancer